REPORTING THE COST-EFFECTIVENESS OF INTERVENTIONS WITH NONSIGNIFICANT EFFECT DIFFERENCES: EXAMPLE FROM A TRIAL OF SECONDARY PREVENTION OF CORONARY HEART DISEASE

Abstract

Cost-effectiveness ratios based on final end points should be calculated even in situations where nonsignificant differences in life-years arise, to avoid publication bias and to provide decision makers with useful information. Uncertainty in the incremental cost-effectiveness ratios should be estimated and presented graphically.